Fostering collaborations and the career of a newly recruited pulmonary scientist

促进新聘肺科科学家的合作和职业生涯

• 批准号: 7936154
• 负责人: RICHARD J MARTIN
• 金额: $ 71.94万
• 依托单位: NATIONAL JEWISH HEALTH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7936154
• 关键词: Address; Adverse effects; Advisory Committees; American; Architecture; Area; Arts; Asthma; Award; Basic Science; Biology; California; Cancer Grant Supplements (P30); Candidate Disease Gene; Caring; Cells; Clinical; Clinical Medicine; Collaborations; Commit; Communities; Community Health; Core Facility; Critical Care; Development; Disease; Doctor of Philosophy; Drug usage; Ensure; Environment; Epithelial Cells; Equilibrium; Evaluation; Faculty; Fostering; Funding; Gene Expression; Gene Expression Profiling; Genes; Glucocorticoid Receptor; Glucocorticoids; Goals; Health; Human Resources; Immune; Internal Medicine; Investigation; Investments; Laboratories; Libraries; Life; Lung; Lung diseases; Manuscripts; Mediating; Medicine; Methods; Modeling; Molecular; Mus; Pathway interactions; Patients; Physicians; Publications; Receptor Signaling; Recruitment Activity; Reporter; Research; Research Infrastructure; Research Personnel; Research Proposals; Resistance; San Francisco; Scientist; Signal Pathway; Signal Transduction; Small Interfering RNA; Therapeutic; Tissues; Training; Universities; Washington; Work; base; career; career development; cell type; clinical practice; direct patient care; falls; follower of religion Jewish; improved; innovation; interest; meetings; member; programs; promoter; success; tool

DESCRIPTION (provided by applicant): The long-term goal of National Jewish Health (NJH) is to improve the lives of patients with lung disease both through direct patient care, and a synergistic combination of clinical, translational and basic research. The general strategy is to recruit physicians and scientists that focus on lung disease and biology, and to foster strong collaborations. Specifically, last fall, NJH undertook a national search for a physician-scientist with an outstanding research background and an interest in airway biology and disease. As a result of this effort, the Pulmonary Division successfully recruited an outstanding, newly independent physician-scientist to join the faculty and conduct research on glucocorticoid signaling. Dr. Anthony Gerber received his MD/Ph.D. at the University of Washington in 1998, and completed his training at the University of California, San Francisco in 2004. He has recently developed an exciting research program on tissue and promoter specific mechanisms of glucocorticoid signaling. This is an area with significant relevance to airway biology and the goals of NJH. Glucocorticoids are among the most widely used drugs in clinical medicine and are central in the treatment of asthma and other immune-mediated diseases. However, severe side effects and resistance complicate their use in clinical practice. A key issue in glucocorticoid receptor (GR) biology and pulmonary therapeutics is to understand the beneficial and harmful effects of glucocorticoid signaling, in particular cell types within the lung, and to define the molecular mechanisms that control these activities. State-of-the-art multiplexed methods to analyze gene expression will be used to address this research area, methods that are broadly applicable to the study of lung disease. With the funds from the PSO award Dr. Gerber's research programs on glucocorticoid signaling will be advanced, collaborations on disease modifying pathways in the lung and multiplexed analysis of gene expression will be facilitated. This will be accomplished by (1) investments in infrastructure for Dr. Gerber's lab and employing skilled personnel to assist with his investigations, (2) integrating tools and methods for multiplexed gene expression analysis into the investigations of other researchers in the division/core, and (3) forming a committee to oversee Dr. Gerber's progress. NJH is at the forefront of the treatment and research of lung and immune-mediated diseases, which afflict millions of Americans. This project will advance the understanding of glucocorticoid signaling, which is central in the treatment of many diseases. It will also foster collaborations among a group of outstanding scientists focused on lung disease.

国家犹太健康（NJH）的长期目标是通过直接的患者护理以及临床，转化和基础研究的协同组合来改善肺部疾病患者的生活。总体战略是招募专注于肺部疾病和生物学的医生和科学家，并促进强有力的合作。具体来说，去年秋天，NJH在全国范围内寻找一位具有杰出研究背景并对气道生物学和疾病感兴趣的医生兼科学家。由于这一努力，肺科成功地招募了一位杰出的，新的独立的医生，科学家加入教师和糖皮质激素信号进行研究。Anthony Gerber博士获得了MD/Ph.D. 1998年在华盛顿大学毕业，并于2004年在加州大学旧金山弗朗西斯科完成培训。他最近开发了一个关于糖皮质激素信号传导的组织和启动子特异性机制的令人兴奋的研究计划。这是一个与气道生物学和NJH的目标有重要关系的领域。糖皮质激素是临床上使用最广泛的药物之一，在治疗哮喘和其他免疫介导的疾病中起着重要作用。然而，严重的副作用和耐药性使其在临床实践中的使用复杂化。糖皮质激素受体（GR）生物学和肺部治疗的一个关键问题是了解糖皮质激素信号传导的有益和有害影响，特别是肺内的细胞类型，并定义控制这些活动的分子机制。分析基因表达的最先进的多重方法将用于解决这一研究领域，这些方法广泛适用于肺部疾病的研究。有了PSO奖的资金，Gerber博士关于糖皮质激素信号传导的研究计划将得到推进，将促进肺部疾病修饰途径和基因表达多重分析的合作。这将通过以下方式实现：（1）投资Gerber博士实验室的基础设施，并雇用熟练的人员协助他的研究，（2）将多路基因表达分析的工具和方法整合到部门/核心的其他研究人员的研究中，以及（3）组建一个委员会来监督Gerber博士的进展。 NJH处于肺部和免疫介导疾病治疗和研究的最前沿，这些疾病困扰着数百万美国人。该项目将推进糖皮质激素信号传导的理解，这是许多疾病治疗的核心。它还将促进一群专注于肺部疾病的杰出科学家之间的合作。

项目成果

Vitamin D and asthma: another dimension.

维生素 D 和哮喘：另一个层面。

• DOI: 10.1164/rccm.201109-1737ed
• 发表时间: 2011
• 期刊: American journal of respiratory and critical care medicine
• 影响因子: 24.7
• 作者: Gerber,AnthonyN;Sutherland,ERand
• 通讯作者: Sutherland,ERand